Stock Market News
Indivior boosted as opioid addiction rival trips over regulatory hurdle
Shares in Indivior received a shot in the arm on Monday after news emerged over the weekend that a rival had hit a regulatory hurdle.
Following approval in December from the US Food and Drug Administration for Indivior's Sublocade, a once-monthly injectable treatment for moderate to severe opioid addiction disorder, sector peer Camurus announced that its rival product had not been approved by the FDA.
The FDA sent complete response letter to Camurus detailing issues with its CAM2038 product, like Sublocade also an injectable buprenorphine, which the company claims should not require any further clinical trials.
There was little detail within the statement other than to inform that Camarus and US marketing partner Braeburn will be working with the FDA to answer key concerns.
Analysts RBC Capital Markets said that it appeared this would results in a launch delay of "at least a year". Broker Numis said the delay could range from three to 10 months "depending on the extent of questions" from the regulator.
"We view this news as a slight positive, albeit with Indivior now responsible for all the heavy lifting associated with a new product/ concept launch," said Numis, noting that conversely, Camurus may well benefit from launching into a better-established premium priced market that Indivior will build through 2018.
RBC agreed it was a positive for Indivior, with a 12-plus month's head-start to entrench its position ahead of the launch of CAM2038.
Given CAM2038 is only delayed rather than turned down, RBC saw this as underpinning its forecasts for Sublocade's launch but we provides "no material valuation benefit yet, unless the delay is more material in length".
Indivior's full year results are due on 15 February.
Following approval in December from the US Food and Drug Administration for Indivior's Sublocade, a once-monthly injectable treatment for moderate to severe opioid addiction disorder, sector peer Camurus announced that its rival product had not been approved by the FDA.
The FDA sent complete response letter to Camurus detailing issues with its CAM2038 product, like Sublocade also an injectable buprenorphine, which the company claims should not require any further clinical trials.
There was little detail within the statement other than to inform that Camarus and US marketing partner Braeburn will be working with the FDA to answer key concerns.
Analysts RBC Capital Markets said that it appeared this would results in a launch delay of "at least a year". Broker Numis said the delay could range from three to 10 months "depending on the extent of questions" from the regulator.
"We view this news as a slight positive, albeit with Indivior now responsible for all the heavy lifting associated with a new product/ concept launch," said Numis, noting that conversely, Camurus may well benefit from launching into a better-established premium priced market that Indivior will build through 2018.
RBC agreed it was a positive for Indivior, with a 12-plus month's head-start to entrench its position ahead of the launch of CAM2038.
Given CAM2038 is only delayed rather than turned down, RBC saw this as underpinning its forecasts for Sublocade's launch but we provides "no material valuation benefit yet, unless the delay is more material in length".
Indivior's full year results are due on 15 February.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price